{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double+Active+dose",
    "query": {
      "intervention": "Double Active dose"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2108,
    "total_pages": 211,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double+Active+dose&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T05:53:44.698Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04134728",
      "title": "Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165 (Otilimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sarilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to GSK3196165/ Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "csDMARDs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2019-10-31",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 46,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04134728"
    },
    {
      "nct_id": "NCT02873936",
      "title": "Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Filgotinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match filgotinib",
          "type": "DRUG"
        },
        {
          "name": "csDMARDs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 449,
      "start_date": "2016-07-27",
      "completion_date": "2018-06-26",
      "has_results": true,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 55,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02873936"
    },
    {
      "nct_id": "NCT04857034",
      "title": "A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Erythematosus, Discoid",
        "Lupus Erythematosus, Subacute Cutaneous"
      ],
      "interventions": [
        {
          "name": "Deucravacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 74,
      "start_date": "2021-07-12",
      "completion_date": "2028-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Irvine, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04857034"
    },
    {
      "nct_id": "NCT06979336",
      "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "RO7837195",
          "type": "DRUG"
        },
        {
          "name": "RO7837195 Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2025-09-29",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 8,
      "location_summary": "Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06979336"
    },
    {
      "nct_id": "NCT02651584",
      "title": "Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid Use Disorders"
      ],
      "interventions": [
        {
          "name": "CAM2038 SC injection",
          "type": "DRUG"
        },
        {
          "name": "SL BPN/NX tabs",
          "type": "DRUG"
        },
        {
          "name": "placebo SC injections",
          "type": "DRUG"
        },
        {
          "name": "SL placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Braeburn Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 428,
      "start_date": "2015-12",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2019-08-22",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Haleyville",
          "state": "Alabama"
        },
        {
          "city": "Hamilton",
          "state": "Alabama"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02651584"
    },
    {
      "nct_id": "NCT00675714",
      "title": "Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "Stable Isotope Infusion Study",
          "type": "PROCEDURE"
        },
        {
          "name": "Collection of blood and tissues",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Humatrope",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "Oxandrolone",
          "type": "DRUG"
        },
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Oxandrolone and propranolol combined",
          "type": "DRUG"
        },
        {
          "name": "Humatrope and propranolol combined",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Exercise--Hospital supervised intensive exercise program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Home exercise program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "Up to 80 Years"
      },
      "enrollment_count": 1126,
      "start_date": "2004-01",
      "completion_date": "2019-07-15",
      "has_results": false,
      "last_update_posted_date": "2019-11-29",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675714"
    },
    {
      "nct_id": "NCT05462106",
      "title": "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyloid Plaque",
        "Beta-Amyloid",
        "DSAD",
        "Prodromal Alzheimer's Disease",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo (Study Part 1a)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose A in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose B in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose C in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Study Part 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose A in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose B in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose C in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Study Part 1b)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AC Immune SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "35 Years to 85 Years"
      },
      "enrollment_count": 304,
      "start_date": "2022-06-21",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lady Lake",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05462106"
    },
    {
      "nct_id": "NCT00763490",
      "title": "Trial Of Double Umbilical Cord Blood Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancies"
      ],
      "interventions": [
        {
          "name": "Full intensity, double umbilical cord, stem cell transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Flu/Bu4 conditioning regimen",
          "type": "DRUG"
        },
        {
          "name": "Total Lymphoid Irradiation (TLI)",
          "type": "RADIATION"
        },
        {
          "name": "Graft versus Host Disease prevention (GVHD prophylaxis)",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2008-12",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2016-12-23",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00763490"
    },
    {
      "nct_id": "NCT03325010",
      "title": "Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "Valbenazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 127,
      "start_date": "2017-10-05",
      "completion_date": "2018-11-16",
      "has_results": true,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 34,
      "location_summary": "Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Clarita",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03325010"
    },
    {
      "nct_id": "NCT04927247",
      "title": "A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-occlusive Crisis",
        "Vaso-occlusive Pain Episode in Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Inclacumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2021-12-09",
      "completion_date": "2023-11-24",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-09-07T05:53:44.698Z",
      "location_count": 17,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04927247"
    }
  ]
}